HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Central nervous system biomarkers for antiobesity drug development.

Abstract
With antiobesity agents, weight loss can emerge from an array of metabolic, cognitive and behavioural changes that translate into weight change over time. In early drug development, characterising these changes can actually be more informative than simply measuring weight loss. Biomarkers for these mechanisms can be used to determine whether potential compounds are worth developing further by providing proof of mechanistic action and detecting early signs of neuropsychiatric adverse effects. In this review, we examine potential biomarkers for effects on metabolism and satiety, hedonics and motivation, and eating behaviour. We also review biomarkers for early detection of neuropsychiatric adverse effects.
AuthorsHisham Ziauddeen, Paul C Fletcher
JournalDrug discovery today (Drug Discov Today) Vol. 18 Issue 23-24 Pg. 1282-91 (Dec 2013) ISSN: 1878-5832 [Electronic] England
PMID23993917 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
Chemical References
  • Anti-Obesity Agents
  • Biomarkers
Topics
  • Animals
  • Anti-Obesity Agents (adverse effects, pharmacology)
  • Biomarkers (metabolism)
  • Central Nervous System (metabolism)
  • Drug Design
  • Feeding Behavior (drug effects)
  • Humans
  • Motivation (drug effects)
  • Obesity (drug therapy)
  • Weight Loss (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: